subject: Pure Bioscience Recieves 7th Patent (NASDAQ:PURE) [print this page] Pure Bioscience Recieves 7th Patent (NASDAQ:PURE)
Pure Bioscience (NASDAQ:PURE) announced the issuance of their seventh patent, number 7,732,486 for anhydrous silver dihydrogen citrate technology. The new technology is more expensive to manufacture according to Michael Krall, CEO, but has advantages and efficiencies for certain applications such as coatings, plastics, latex, polymers, textiles, bandages and other wound care applications.
PURE reported a net loss for the third quarter of$ .05 a share or $1,610,000, an increase from a net loss of $1,545,600. Although the losses have widened slightly from a year ago, management was happy with product revenue growth, increasing from $275,300 to $1,112,300 from a year ago. It was also noted that the company had made significant progress on certain partner programs that will aid in mid to long term growth. Finally, the company received a key U.S. EPA registration for IV-7 Ultimate Germ Defense for Food Contact Surfaces which is used to disinfect food touching surfaces, and will now be an added revenue stream in the second half of 2010.
PURE Biosciences has patents in approximately 70 countries and is dedicated to providing solutions for world healthcare problems such as staph infection. The company's technology is meant to be high efficacy and low toxicity, engaging in the world's green movement.
PURE is currently trading at 2.91 down .12 or 4.02% on a volume of 138k. Although the company is down today, over the past three months, and year PURE has increased in equity price, increasing from $1.61 to the low $3.00.
For More stories written on PURE click here
Disclosure: no positions
To view this article at World Market Media click on the link below: http://www.worldmarketmedia.com/779/section.aspx/1797/post/pure-bioscience-recieves-7th-patent-nasdaqpure
